Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
about
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology studyMaternal metabolism and obesity: modifiable determinants of pregnancy outcomeDiabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesPlace of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statementApplicability of the Existing CVD Risk Assessment Tools to Type II Diabetics in Oman: A ReviewAssessing the analytical performance of systems for self-monitoring of blood glucose: concepts of performance evaluation and definition of metrological key termsThe risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studiesTranscription Factor Runx2 Promotes Aortic Fibrosis and Stiffness in Type 2 Diabetes Mellitus.Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsRace, regionality and pre-diabetes in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) studyClinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes RegisterThe cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker ratsEarly renal dysfunction after contrast media administration despite prophylactic hydrationEffects of intensive glucose lowering in type 2 diabetesPro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.Common carotid intima-media thickness does not add to Framingham risk score in individuals with diabetes mellitus: the USE-IMT initiative.Combination of single quantitative parameters into multiparametric model for ischemia detection is not superior to visual assessment during dobutamine stress echocardiography.The glucose triad and its role in comprehensive glycaemic control: current status, future management.Left ventricular hypertrophy and insulin resistance in adults from an urban community in The Gambia: cross-sectional study.Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline dataCharacteristics, management and attainment of lipid target levels in diabetic and cardiac patients enrolled in Disease Management Program versus those in routine care: LUTZ registry.Diabetes mellitus and mortality after acute coronary syndrome as a first or recurrent cardiovascular event.Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.Linoleic acid suppresses cholesterol efflux and ATP-binding cassette transporters in murine bone marrow-derived macrophagesEffectiveness of a training course for general practice nurses in motivation support in type 2 diabetes care: a cluster-randomised trialSerum gamma-glutamyl transferase: a novel biomarker for coronary artery disease.Using family history information to promote healthy lifestyles and prevent diseases; a discussion of the evidence.Screening asymptomatic patients with diabetes for unknown coronary artery disease: does it reduce risk? An open-label randomized trial comparing a strategy based on exercise testing aimed at revascularization with management based on pharmacologicalMarkers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review.Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study.Hypertension and diabetes: should we treat early surrogates? What are the cons?Self-monitoring of blood glucose as part of the integral care of type 2 diabetesTrends in diabetes and obesity in Samoa over 35 years, 1978-2013.First nationwide survey on cardiovascular risk factors in Grand-Duchy of Luxembourg (ORISCAV-LUX)Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers.Educational Health Disparities in Cardiovascular Disease Risk Factors: Findings from Jamaica Health and Lifestyle Survey 2007-2008.Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients.Holistic approach to prevention and management of type 2 diabetes mellitus in a family setting.
P2860
Q22242896-8D0C5645-E51D-4BCB-861C-49F16C867011Q24289043-90E9BF4D-B9F2-4963-ADA9-7602C096CD2FQ24604436-0CE2FA25-D222-4D87-BCFD-78164AF616A7Q24608301-801E0A9E-C3D6-46BE-A0C2-DD5BC2637FFDQ26783199-A0EAAF2D-2BB2-44DB-956B-F000F3726577Q26784142-1F435242-BBDE-45DB-82DC-6CB27A862352Q26996709-962CE65F-543D-4359-AE36-A35F4070F974Q26999933-E1E00623-74D6-4316-85D7-0CF0ADD389FBQ27339475-D8866E3E-1A71-4574-ADB9-C016979837B7Q28072765-D4CD4834-8309-496A-B8FC-23993BA91D66Q28392183-356A9A00-BA8C-486E-9291-DF7B57CE25C5Q28477948-8BEDE56C-BD46-446B-B6F6-A1AA2ED033E9Q28579415-A5F6862E-9917-44C4-A1EF-C267F5E3FB44Q28680679-D73DB255-66AF-4EB1-AA6B-C0B8879F087EQ29547736-9FC888FD-58AF-4FF6-90B1-F4C4570B269FQ30234356-68012A2B-E218-4CDD-AAC2-E55945548AB7Q30371511-336A1114-B307-4E26-AC51-6A26B552DD75Q30385947-2FE8A646-E135-4FA1-BD7F-F19FDA39254EQ30393989-71B1D445-1ED5-41D3-B054-334E0CADBAF4Q30440409-524B91B0-4DFD-448F-BA69-BFE0E2BE3C85Q30530802-64DDC4C3-2999-462F-9665-DF1253313EB3Q30871991-990AC81D-D5A1-4989-AEA4-6DD08DD568D9Q33378481-64B403F8-F241-4EF7-98B7-03B98C43480BQ33501445-D0DA1D2E-B2A0-44F8-8672-1550CCF56023Q33515541-19F18B99-7151-45FB-9C17-289BBA84A51FQ33565875-BF21A19B-13C4-4F88-984F-B443F5718440Q33568081-95F289D0-E13C-4BD1-8F21-03C42BC2FF6CQ33568430-31ACE3BD-73CF-4617-9F2E-289B7A56C4CFQ33577414-0DA286DC-B7CB-4B65-8E0D-7508D91853FAQ33587274-EE8BA472-1E79-4F7D-94FC-F9A6D384D6DDQ33593039-D9059399-D2E9-4208-9F39-D9C872B2DEF6Q33602214-414B40B3-BDA9-42FA-9735-D0043D105905Q33610656-19C270E7-6E7A-46CE-B6E5-AC9BDC4B484EQ33610848-C8E636EF-7510-457E-BCE0-6286549825EDQ33621501-43479F0C-2ADF-46C5-9655-25D8C41D9B14Q33653585-DC252EE3-A261-4598-AB55-902F2346A5F9Q33659058-0BC7586A-06F9-49B5-AFAE-8358DA029ED1Q33679383-0018BA09-7ACC-40D1-836A-F745080C1FD4Q33682300-D4698E55-D123-4679-89E5-40C51C3693D7Q33706603-BB60DE5B-8224-48B5-AB62-AB78AA860D6F
P2860
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
description
im Juni 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2006
@uk
name
Guidelines on diabetes, pre-di ...... r the Study of Diabetes (EASD)
@en
Guidelines on diabetes, pre-di ...... r the Study of Diabetes (EASD)
@nl
type
label
Guidelines on diabetes, pre-di ...... r the Study of Diabetes (EASD)
@en
Guidelines on diabetes, pre-di ...... r the Study of Diabetes (EASD)
@nl
prefLabel
Guidelines on diabetes, pre-di ...... r the Study of Diabetes (EASD)
@en
Guidelines on diabetes, pre-di ...... r the Study of Diabetes (EASD)
@nl
P2093
P50
P356
P1476
Guidelines on diabetes, pre-di ...... r the Study of Diabetes (EASD)
@en
P2093
A. Osterspey
B. Charbonnel
B. Jonsson
E. Erdmann
E. Ferrannini
F. Cosentino
G. Schernthaner
P304
P356
10.1093/EURHEARTJ/EHL260
P50
P577
2006-06-13T00:00:00Z